



AB The present invention involves novel methods of using N-aryl-2-sulfonamidobenzamides as phosphate (Pi) transport inhibitors for the selective inhibition of Pi transport in the kidney and/or intestine as a therapeutic treatment in chronic renal failure and uremic bone disease and other related diseases. Preferably, inhibitors for use herein are those which selectively inhibit Na<sup>+</sup>-dependent Pi transport in tissues.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:911023 CAPLUS

DOCUMENT NUMBER: 134:51396

TITLE: Sulfonamidobenzanilide macrophage scavenger receptor antagonists and therapeutic use thereof

INVENTOR(S): Weinstock, Joseph; Franz, Robert G.; Gaitanopoulos, Dimitri E.

PATENT ASSIGNEE(S): SmithKline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 21 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000078145	A1	20001228	WO 2000-US16988	20000621
W: AE, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CZ, DZ, EE, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2377288	AA	20001228	CA 2000-2377288	20000621
BR 2000011571	A	20020305	BR 2000-11571	20000621
EP 1187531	A1	20020320	EP 2000-944763	20000621
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200103696	T2	20020621	TR 2001-3696	20000621
JP 2003502347	T2	20030121	JP 2001-504226	20000621
US 6458845	B1	20021001	US 2001-18457	20011212
NO 2001006077	A	20011213	NO 2001-6077	20011213